Christopher A Fausel

Summary

Affiliation: Clarian Health Partners
Country: USA

Publications

  1. ncbi request reprint Novel treatment strategies for chronic myeloid leukemia
    Christopher A Fausel
    Hematology Oncology Bone Marrow Transplant, Indiana University Cancer Center, Indianapolis, IN 46202, USA
    Am J Health Syst Pharm 63:S15-20; quiz S21-2. 2006
  2. ncbi request reprint Targeted chronic myeloid leukemia therapy: Seeking a cure
    Christopher Fausel
    Hematology Oncology BMT, Indiana University Cancer Center, 550 North University Boulevard, Indianapolis, IN 46202, USA
    Am J Health Syst Pharm 64:S9-15. 2007
  3. ncbi request reprint Targeted chronic myeloid leukemia therapy: seeking a cure
    Christopher Fausel
    Indiana University, Cancer Center, Indianapolis, IN, USA
    J Manag Care Pharm 13:8-12. 2007

Detail Information

Publications3

  1. ncbi request reprint Novel treatment strategies for chronic myeloid leukemia
    Christopher A Fausel
    Hematology Oncology Bone Marrow Transplant, Indiana University Cancer Center, Indianapolis, IN 46202, USA
    Am J Health Syst Pharm 63:S15-20; quiz S21-2. 2006
    ..Mutations of the BCR-ABL kinase domain, a common mechanism of resistance to imatinib in CML, are discussed...
  2. ncbi request reprint Targeted chronic myeloid leukemia therapy: Seeking a cure
    Christopher Fausel
    Hematology Oncology BMT, Indiana University Cancer Center, 550 North University Boulevard, Indianapolis, IN 46202, USA
    Am J Health Syst Pharm 64:S9-15. 2007
    ..This article focuses on imatinib, how it has altered CML therapy, clinical trials that are the basis for its efficacy, and adverse effects associated with its current clinical use...
  3. ncbi request reprint Targeted chronic myeloid leukemia therapy: seeking a cure
    Christopher Fausel
    Indiana University, Cancer Center, Indianapolis, IN, USA
    J Manag Care Pharm 13:8-12. 2007
    ..BCR-ABL inhibitors, such as imatinib, are proof that targeting specific genetic mutations associated with cancer yields a high degree of efficacy with minimal toxicity...